Attenuation of fibroblast proliferation

Details Attenuation of fibroblast proliferation Attenuation of fibroblast proliferation

2006-06-06

2006-06-06

Meller, Michael (Department: 1655)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Reexamination Certificate

active

07056711

ABSTRACT:
Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B(dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.

REFERENCES:
patent: 5695752 (1997-12-01), Rosen et al.
patent: 5985582 (1999-11-01), Triscott
patent: 6153187 (2000-11-01), Yacoby-Zeevi
patent: WO 95/13091 (1995-05-01), None
patent: WO 96/01894 (1996-01-01), None
patent: WO 98/46258 (1998-10-01), None
patent: WO 99/484778 (1999-09-01), None
Bensadoun,et al. “Proteoglycan deposition in pulmonary fibrosis,”Amer. J. Respir. Crit. Care Med. 154:1819-1828 (1996).
Denholm & Phan, “The effects of bleomycin on alveolar macrophage growth factor secretion,”Amer. J. Pathol. 134:355-363 (1989).
Denholm, “Inhibition of fibroblast by Chondrotinase AC(CAC) and Chondrotinase B(CB),”FASEB J12(5):A948 1998).
Denholm, et al., “Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate,”European Journal of Pharmacology400:145-153 (2000).
Donati, et al., “Treatment of hyertrophic and keloid cicatrices with thiomucase.”Minerva Chirurgica30(6):326-33 AN-Medline 76196588 (1975).
Fannon & Nugent, “Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate,”J. Biol. Chem. 271:17949-17956 (1996).
Forrester, et al., “A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies,”J. Am. Coll. Cardiol. 17:758-769 (1991).
Jackson, et. al., “Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes,”Physiol. Rev. 71:481-530 (1991).
Keller, et al., “Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate,”Biochem. 28:8100-8107 (1989).
Kjellen & Lindahl, “Proteoglycans: structures and interactions,”Ann. Rev. Biochem. 60:443-475 (1991).
Linhardt, et al., “Polysaccharide lyases,”Appl. Biochem. Biotech. 12:135-175 (1986).
Linn, et al. “Isolation and characterization of two chondroitin lyases from Bacteroides thetaiotaomicron,”J. Bacteriol. 156:859-866 (1983).
Liu & Connolly, “Isolation and characterization of two chondroitin lyases from Bacteroides thetaiotaomicron,”Sem. Cutaneous Med. and Surg. 17:3-11 (1998).
Lyon, et al., “Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate,”J. Biol. Chem. 273:271-278 (1998).
Maeda, et al., “6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM),”J. Biol. Chem. 271:21446-21452 (1996).
Miao, et al., “Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor,”J. Cell. Biochem. 57:173-184 (1995).
Michelacci, et al., “Isolation and characterization of an induced chondroitinase ABC from Flavobacterium heparinum,”Biochim. Biophys. Acta. 923:291-201 (1987).
Milev, et al., “The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity,”J. Biol. Chem. 273:21439-21442 (1998).
Penc & Gallo, “Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function,”J. Biol. Chem. 273:28116-28121 (1998).
Phan & Kunkel, “Lung cytokine production in bleomycin-induced pulmonary fibrosis,”Exper. Lung Res. 18:29-43 (1992).
Richardson & Hatton, “Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing,”Exp. Mol. Pathol. 58:77-95 (1993).
Sato, et. al., “Submit structure of Chondroitinase ABC fromProteus vulgaris,” Agric. Biol. Chem. 50:1057-1059 (1986).
Schmidt, et al., “The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues,”J. Biol. Chem. 267:19242-19247 (1992).
Schwartz, “Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein,”J. Biol. Chem. 252:6316-6321 (1977).
Segarini, et al., “Binding of transforming growth factor-beta to cell surface proteins varies with cell type,”Molecular Endocrinol. 3:261-272 (1989).
Sundberg, et al., “Development and progression of psoriasiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant,”Pathobiology65:271-286 (1997).
Tabas, et al., “Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation,”J. Biol. Chem. 268(27):20419-20432 (1993).
Tao, et al., “Elevated expression of proteoglycans in proliferating vascular smooth muscle cells,”Atherosclerosis135:171-179 (1997).
Varani, et al., “Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion,”Amer. J. Pathol. 145:561-573 (1994).
Vlodavsky, et al., “Control of cell proliferation by heparan sulfate and heparin-binding growth factors,”Thrombosis Haemostasis74:534-540 (1995).
Yamagata, et al., “Purification and properties of bacterial chondroitinases and chondrosulfatases,”J. Biol. Chem. 243:1523-1535 (1968).
Yayon, et al., “Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor,”Cell64:841:848 (1991).
Yeo, et al. Alterations in proteoglycan synthesis common to healing wounds and tumors,Amer. J. Pathol. 138:1437-1450 (1991).
Zhang, et al., “In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection,”Lab. Invest. 70: 192-202 (1994).

Affiliated with

Also associated with

Rating

Attenuation of fibroblast proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuation of fibroblast proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuation of fibroblast proliferation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3680647